DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:DBD • US2536512021

71.81 USD
+2.46 (+3.55%)
At close: Feb 6, 2026
71.81 USD
0 (0%)
After Hours: 2/6/2026, 8:27:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

DBD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 34 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has an average financial health and profitability rating. DBD has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • DBD had positive earnings in the past year.
  • DBD had a positive operating cash flow in the past year.
  • DBD had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
DBD Yearly Net Income VS EBIT VS OCF VS FCFDBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • With a decent Return On Assets value of 1.36%, DBD is doing good in the industry, outperforming 67.65% of the companies in the same industry.
  • The Return On Equity of DBD (4.57%) is better than 76.47% of its industry peers.
  • DBD's Return On Invested Capital of 8.85% is fine compared to the rest of the industry. DBD outperforms 70.59% of its industry peers.
  • DBD had an Average Return On Invested Capital over the past 3 years of 5.12%. This is significantly below the industry average of 16.39%.
  • The 3 year average ROIC (5.12%) for DBD is below the current ROIC(8.85%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.36%
ROE 4.57%
ROIC 8.85%
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
DBD Yearly ROA, ROE, ROICDBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

  • DBD's Profit Margin of 1.37% is fine compared to the rest of the industry. DBD outperforms 67.65% of its industry peers.
  • Looking at the Operating Margin, with a value of 7.47%, DBD is in the better half of the industry, outperforming 79.41% of the companies in the same industry.
  • In the last couple of years the Operating Margin of DBD has grown nicely.
  • DBD has a Gross Margin (25.48%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
Industry RankSector Rank
OM 7.47%
PM (TTM) 1.37%
GM 25.48%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
DBD Yearly Profit, Operating, Gross MarginsDBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • DBD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, DBD has about the same amount of shares outstanding.
  • The number of shares outstanding for DBD has been reduced compared to 5 years ago.
  • Compared to 1 year ago, DBD has an improved debt to assets ratio.
DBD Yearly Shares OutstandingDBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
DBD Yearly Total Debt VS Total AssetsDBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

  • An Altman-Z score of 1.97 indicates that DBD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • DBD has a better Altman-Z score (1.97) than 61.76% of its industry peers.
  • The Debt to FCF ratio of DBD is 3.71, which is a good value as it means it would take DBD, 3.71 years of fcf income to pay off all of its debts.
  • DBD has a Debt to FCF ratio of 3.71. This is in the better half of the industry: DBD outperforms 67.65% of its industry peers.
  • A Debt/Equity ratio of 0.84 indicates that DBD is somewhat dependend on debt financing.
  • DBD has a Debt to Equity ratio of 0.84. This is comparable to the rest of the industry: DBD outperforms 44.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 3.71
Altman-Z 1.97
ROIC/WACC0.94
WACC9.4%
DBD Yearly LT Debt VS Equity VS FCFDBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

  • DBD has a Current Ratio of 1.36. This is a normal value and indicates that DBD is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.36, DBD perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
  • DBD has a Quick Ratio of 1.36. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.89, DBD perfoms like the industry average, outperforming 52.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 0.89
DBD Yearly Current Assets VS Current LiabilitesDBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for DBD have decreased strongly by -38.07% in the last year.
  • Measured over the past years, DBD shows a very strong growth in Earnings Per Share. The EPS has been growing by 69.69% on average per year.
  • Looking at the last year, DBD shows a decrease in Revenue. The Revenue has decreased by -2.86% in the last year.
  • Measured over the past years, DBD shows a decrease in Revenue. The Revenue has been decreasing by -3.18% on average per year.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%

3.2 Future

  • Based on estimates for the next years, DBD will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.21% on average per year.
  • Based on estimates for the next years, DBD will show a small growth in Revenue. The Revenue will grow by 2.51% on average per year.
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DBD Yearly Revenue VS EstimatesDBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B
DBD Yearly EPS VS EstimatesDBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 19.62, which indicates a rather expensive current valuation of DBD.
  • 73.53% of the companies in the same industry are more expensive than DBD, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 27.92, DBD is valued a bit cheaper.
  • A Price/Forward Earnings ratio of 14.61 indicates a correct valuation of DBD.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of DBD indicates a somewhat cheap valuation: DBD is cheaper than 67.65% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.78. DBD is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 19.62
Fwd PE 14.61
DBD Price Earnings VS Forward Price EarningsDBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • DBD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DBD is cheaper than 94.12% of the companies in the same industry.
  • DBD's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. DBD is cheaper than 79.41% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.24
EV/EBITDA 7.65
DBD Per share dataDBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DBD does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as DBD's earnings are expected to grow with 19.21% in the coming years.
PEG (NY)2.22
PEG (5Y)N/A
EPS Next 2Y12.85%
EPS Next 3Y19.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DBD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DIEBOLD NIXDORF INC

NYSE:DBD (2/6/2026, 8:27:26 PM)

After market: 71.81 0 (0%)

71.81

+2.46 (+3.55%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)11-05
Earnings (Next)02-12
Inst Owners105.4%
Inst Owner Change-0.73%
Ins Owners1.81%
Ins Owner Change-0.17%
Market Cap2.58B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price Target80.58 (12.21%)
Short Float %2.32%
Short Ratio3.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)0%
PT rev (3m)4.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.72%
EPS NY rev (1m)0%
EPS NY rev (3m)12.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.36%
Valuation
Industry RankSector Rank
PE 19.62
Fwd PE 14.61
P/S 0.7
P/FCF 10.24
P/OCF 9.22
P/B 2.33
P/tB N/A
EV/EBITDA 7.65
EPS(TTM)3.66
EY5.1%
EPS(NY)4.92
Fwd EY6.84%
FCF(TTM)7.01
FCFY9.77%
OCF(TTM)7.79
OCFY10.85%
SpS102.88
BVpS30.87
TBVpS-9.56
PEG (NY)2.22
PEG (5Y)N/A
Graham Number50.42
Profitability
Industry RankSector Rank
ROA 1.36%
ROE 4.57%
ROCE 11.2%
ROIC 8.85%
ROICexc 9.91%
ROICexgc 29.15%
OM 7.47%
PM (TTM) 1.37%
GM 25.48%
FCFM 6.82%
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 3.71
Debt/EBITDA 2.28
Cap/Depr 20.59%
Cap/Sales 0.75%
Interest Coverage 2.89
Cash Conversion 68.06%
Profit Quality 497.23%
Current Ratio 1.36
Quick Ratio 0.89
Altman-Z 1.97
F-Score7
WACC9.4%
ROIC/WACC0.94
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.55%
EBIT Next 3Y14.01%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%

DIEBOLD NIXDORF INC / DBD FAQ

What is the fundamental rating for DBD stock?

ChartMill assigns a fundamental rating of 4 / 10 to DBD.


Can you provide the valuation status for DIEBOLD NIXDORF INC?

ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.


What is the profitability of DBD stock?

DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.


What is the financial health of DIEBOLD NIXDORF INC (DBD) stock?

The financial health rating of DIEBOLD NIXDORF INC (DBD) is 5 / 10.


How sustainable is the dividend of DIEBOLD NIXDORF INC (DBD) stock?

The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.